Every 8-K that Teladoc Health, Inc. (TDOC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TDOC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TDOC filings page.
Teladoc Health, Inc. (TDOC) appointed Michael Grasher as Chief Financial Officer, effective August 31, 2026, while Charles Divita III continues as Chief Executive Officer. Grasher brings over three decades of financial and insurance-sector experience, including CFO roles at IFG Companies, Fortegra Group and AMERISAFE, Inc., plus prior equity research experience.
His offer includes a $550,000 base salary, a one-time $500,000 sign-on bonus, an annual bonus target of 85% of base salary beginning in 2027, and a new-hire equity award with a target value of $3,000,000, split 50% restricted stock units and 50% performance stock units tied to 2026 adjusted EBITDA and 2026–2028 revenue CAGR, with multi-year vesting. An employment agreement provides salary, bonus-related amounts, health benefits and equity vesting acceleration upon certain terminations, with enhanced benefits if a qualifying termination occurs within 12 months after a change of control.
Teladoc Health, Inc. reported a planned board change. On August 10, 2026, director David B. Snow, Jr. informed the company of his intention to retire from its Board of Directors, effective September 30, 2026. He has served as a director since 2014.
The company states that Mr. Snow is retiring for personal reasons and that his decision is not due to any disagreement with the company on any matter. Teladoc expressed its appreciation for his dedicated service.
Teladoc Health, Inc. increased its Board of Directors to ten members and appointed Mark V. Anquillare as an independent director effective August 3, 2026. He joins both the audit and compensation committees and has been designated an “audit committee financial expert” under SEC and New York Stock Exchange rules.
The company states there are no related-party arrangements or transactions requiring disclosure in connection with his appointment. Anquillare will receive the same indemnification protections and be eligible for the standard compensation programs for Teladoc Health’s non‑employee directors. A press release announcing his appointment was issued on August 3, 2026.
Teladoc Health reported Second Quarter 2026 revenue of $606.9 million, down 4% year over year, and a net loss of $38.9 million, or $0.21 per share. Adjusted EBITDA was $65.7 million, a 5% decrease from the prior year, and results were within previously communicated consolidated guidance ranges.
The Integrated Care segment generated revenue of $394.3 million, up 1%, with adjusted EBITDA of $65.2 million and a 16.5% margin, compared with 14.7% a year earlier. U.S. Integrated Care members totaled 100.3 million and chronic care program enrollment rose 14% to 1.272 million. BetterHelp revenue declined 12% to $212.6 million, and adjusted EBITDA fell to $0.5 million, a 0.2% margin, amid weaker cash-pay demand and rapid growth in insurance-covered services.
For the first six months of 2026, revenue declined 3% to $1.22 billion and net loss was $102.7 million, versus $125.7 million in 2025, when results included a $59.1 million non-cash goodwill impairment. Second Quarter 2026 operating cash flow was $64.7 million and free cash flow $35.7 million. For full-year 2026, Teladoc forecasts revenue of $2.362–$2.447 billion, adjusted EBITDA of $271–$303 million, free cash flow of $130–$170 million, and a net loss per share between $1.00 and $0.75.
Teladoc Health, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected all nine director nominees to serve until the 2027 annual meeting, with each receiving more votes in favor than against.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 71,154,268 votes for and 8,973,257 against. In addition, they ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 122,580,992 votes for and 1,195,800 against.
Teladoc Health reported First Quarter 2026 revenue of $613.8 million, down 2% from a year earlier, as access-fee revenue declined but other revenue grew. U.S. revenue fell 6% while international revenue rose 17%, reflecting mixed geographic trends.
The company posted a net loss of $63.8 million, or $0.36 per share, improving from a $93.0 million loss last year, helped by the absence of a prior goodwill impairment. Adjusted EBITDA was $58.2 million, essentially flat. Management reaffirmed the midpoint of its full‑year 2026 outlook, including expected revenue of $2.48‑$2.58 billion and positive free cash flow.
Teladoc Health, Inc. expanded its board of directors to nine members and appointed Susan R. Salka as a new director, effective March 30, 2026. She will serve on the board’s audit and compensation committees, and has been designated an independent director and an “audit committee financial expert.” Ms. Salka is the former president and CEO of AMN Healthcare Services, where over a 33‑year tenure she helped drive 26 acquisitions and grow revenue to over $5 billion. She also brings prior board experience at several major healthcare and life sciences companies.
Teladoc Health reported Fourth Quarter 2025 revenue of $642.3 million, roughly flat year-over-year, and a net loss of $25.1 million, or $0.14 per share. Adjusted EBITDA rose 12% to $83.8 million as Integrated Care offset softer BetterHelp performance.
For Full Year 2025, revenue declined 2% to $2.53 billion while net loss narrowed sharply to $200.3 million from $1.00 billion, helped by much lower goodwill impairments. Adjusted EBITDA fell 10% to $281.1 million. Operating cash flow was $294.4 million and free cash flow was $166.9 million. Guidance for 2026 calls for revenue of $2.47–$2.59 billion, adjusted EBITDA of $266–$308 million, and free cash flow of $130–$170 million, with Integrated Care growing modestly and BetterHelp expected to decline or remain roughly flat.
Teladoc Health expanded its board of directors and appointed Michael Smith as a new independent director, effective February 18, 2026. He was also named to the audit committee and the nominating and corporate governance committee, and is designated an “audit committee financial expert” under SEC and NYSE rules.
Smith brings more than three decades of experience in insurance and financial services, including senior roles at Voya Financial and Lincoln Financial, and currently serves as Executive Chairman of Talcott Financial Group. Teladoc Health also announced it will release fourth quarter 2025 results on February 25, 2026, followed by a conference call at 5:00 p.m. ET.
Teladoc Health, Inc. reported that long-serving director Thomas G. McKinley notified the company on February 8, 2026 of his intention to retire from the Board, effective February 20, 2026. The company states that Mr. McKinley is retiring for personal reasons and not due to any disagreement with the company on any matter.
Teladoc Health, Inc. disclosed that board member J. Eric Evans plans to retire from its Board of Directors. He informed the company on December 11, 2025 that he will not stand for reelection at Teladoc Health’s 2026 Annual Meeting of Stockholders and will retire from the Board at the conclusion of that meeting.
Mr. Evans has served as a director since 2023. The company notes that he is retiring for personal reasons and that his decision is not due to any disagreement with Teladoc Health on any matter.
Teladoc Health, Inc. reported that on December 9, 2025 it amended its 2023 Employment Inducement Incentive Award Plan. The amendment increases the number of shares of common stock reserved for issuance under the 2023 Inducement Plan by 1,780,000 shares, bringing the total reserve to 7,280,000 shares of common stock.
This plan is used to grant equity awards to new employees as inducement for joining the company. Teladoc notes that the 2023 Inducement Plan was adopted by the Board without stockholder approval in reliance on NYSE Rule 303A.08, which permits certain inducement awards without a shareholder vote.
Teladoc Health, Inc. furnished an 8‑K to announce it issued a press release with its third‑quarter 2025 financial results. The press release is attached as Exhibit 99.1 and dated October 29, 2025.
The company states the information is being furnished, not filed under the Exchange Act, and therefore is not subject to Section 18 liabilities, nor incorporated into Securities Act filings unless specifically referenced.
Teladoc Health (TDOC) announced preliminary Q3 2025 results, noting they are unaudited and subject to change as the company completes its closing process. The company also stated it continues to expect its consolidated full-year 2025 results to be consistent with the outlook range disclosed on July 29, 2025. A press release with additional details, including non-GAAP measures and reconciliations, was furnished as Exhibit 99.1.
The company also disclosed a leadership change: Chief Financial Officer Mala Murthy informed Teladoc of her resignation effective November 21, 2025. She is expected to present on the company’s third-quarter conference call on October 29, 2025. The company indicated her decision was for personal reasons and not due to any disagreement regarding operations, policies, or practices. The information in the press release and items referenced was furnished, not filed.